HOME >> BIOLOGY >> NEWS
Multilateral Initiative on Malaria Secretariat to move to Sweden

National Institutes of Health, Bethesda, Maryland -- The Fogarty International Center (FIC) of the National Institutes of Health (NIH) announces today that Stockholm University, Karolinska Institute, and the Swedish Institute for Infectious Disease Control have been selected to serve as Secretariat of the Multilateral Initiative on Malaria (MIM) for 2003 to 2005. Since 1999 FIC has served as Secretariat of MIM, working in close cooperation with NIH's National Institute of Allergy and Infectious Diseases and National Library of Medicine on behalf of MIM's sponsoring agencies. The transfer of the MIM Secretariat will take place shortly after the Third MIM Pan-African Malaria Conference, which will be held in November 2002 in Arusha, Tanzania.

MIM is an international alliance of research and public health agencies and African scientists that was established in 1997 in Dakar, Senegal, at the first Pan-African Malaria Conference. MIM's objectives are to stimulate and support collaborative research to address the needs of public health programs in malaria-endemic countries; to modernize communication systems used by the African research community; and to strengthen research capacity and human resources in those parts of the world where the disease is most widely spread, mainly in Africa, but also in South America and Asia.

Malaria kills 2.7 million people each year, according to the most recent estimates, and is responsible for enormous economic burdens in malaria-endemic regions. Over 75 percent of those who die of malaria are African children under the age of 5. Over 1.5 billion new infections occur annually. Unfortunately, these numbers are on the rise due to insecticide resistance, antimalarial drug resistance, and environmental changes. Unless new strategies are developed, death and illness due to malaria will increase, and the disease will continue to be a substantial barrier to the economic and social development of malaria-endemic regio
'"/>

Contact: Jennifer Cabe
jennifercabe@nih.gov
301-496-2075
NIH/Fogarty International Center
13-Aug-2002


Page: 1 2 3

Related biology news :

1. Keck Futures Initiative announces grant recipients
2. GenVec, U.S. NMRC, and PATHs Malaria Vaccine Initiative partner to expand malaria vaccine efforts
3. Hydrogen Initiative report from American Physical Society panel released
4. Open Access Initiative from Oxford Journals
5. Initiative launched for computer science
6. Sustainable Forestry Initiative Standard enhanced with new measures to protect biodiversity
7. Food & Agriculture Biosecurity Initiative announced by incoming executive dean at Rutgers
8. Initiative considers changing face of biology
9. Largest grant ever to Indiana U fuels Genomics Initiative
10. Winners of the DFG Bioinformatics Initiative
11. UWs new Cell Systems Initiative welcomes Immunex collaboration

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Multilateral Initiative Malaria Secretariat move Sweden

(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
(Date:5/21/2013)... modifications, which alter the way genes function without ... detected in the blood of pregnant women during ... foretell depression in the weeks after giving birth, ... debilitating. , The findings of the small study ... the journal Molecular Psychiatry . , "Postpartum ...
(Date:5/20/2013)... to the antibiotic colistin are also commonly resistant ... according to a study in mBio , ... for Microbiology. Cross-resistance to colistin and host antimicrobials ... against bacterial attack, could mean that patients with ... a crippled immune response. Colistin is a last-line ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013 Many have long ... contributor to acne. Recently physicians from Clinical Psychiatry.com ... stress on the skin, and suggested using hypnotherapy ... the chemicals produced from stress that cause acne. , ... negative feelings acne brings about, stress causes changes in ...
(Date:5/21/2013)... Emerson Resources Inc. , a premier pharmaceutical ... Company’s Chief Executive Officer and Chairman of the Board, ... service. As part of Emerson Resources’ planned leadership succession ... as Dr. Signorino’s successor. , Dr. Signorino is ... a significant contribution to the field during his extensive ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: